New drug cocktail takes on glioblastoma in early trial

NCT ID NCT03587038

Ongoing Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests whether adding an experimental drug called OKN-007 to standard chemoradiotherapy is safe and tolerable for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 27 participants will receive the combination after surgery. The main goal is to find the best dose and check for side effects, with a secondary look at how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OKN-007 (a drug) combined with temozolomide (chemotherapy) and radiation therapy
What this could lead to: If it works, this could point toward a new treatment option for glioblastoma, a tough brain cancer, by improving how well standard therapy works.
What could go wrong: This is a very early, small pilot study (27 people) focused on safety, not effectiveness. The drug combination may not work better than standard care and could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Stephenson Cancer Center, University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73117, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.